Asia PacificENPublic drug registration overview
Japan Pharmaceutical Registration Pathway
Market Overview Market profile: Japan is a highvalue pharmaceutical market. PMDA review quality, NHI pricing, Japanese dossier materials, and local MAH structure are critical. Regu...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in or register to view the complete pharmaceutical country report.
AI Citation Summary
- Country: Japan Pharmaceutical Registration Pathway
- Product line: Pharmaceuticals
- Regulator / source: Regulatory maturity: High. PMDA conducts scientific review and consultation; MHLW grants approvals.
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Regulators typically question safety, efficacy, quality, GMP, BE/clinical evidence, labeling, and risk management. Project plans should reserve at least one deficiency-response cycle and should not treat official target timelines as guaranteed launch dates.
- Key fees: Marketing authorisation for medicines in Japan is generally managed by Ministry of Health, Labour and Welfare (MHLW). For a foreign company, the project is not only a technical dossier submission. It also requires a local applicant or holder, importer or representative, manufacturing-site GMP evidence, labeling, post-market safety responsibility, and future variation control. The official entry point should be checked through https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html before project launch for current forms, systems, fees, and guidance.
- Local requirement: Marketing authorisation for medicines in Japan is generally managed by Ministry of Health, Labour and Welfare (MHLW). For a foreign company, the project is not only a technical dossier submission. It also requires a local applicant or holder, importer or representative, manufacturing-site GMP evidence, labeling, post-market safety responsibility, and future variation control. The official entry point should be checked through https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html before project launch for current forms, systems, fees, and guidance.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Japan Pharmaceutical Registration Pathway
Market Overview
- Market profile: Japan is a high-value pharmaceutical market. PMDA review quality, NHI pricing, Japanese dossier materials, and local MAH structure are critical.
- Regulatory maturity: High. PMDA conducts scientific review and consultation; MHLW grants approvals.
- Core decision: Determine whether the product is new drug, generic, biologic, regenerative product, or OTC and define Japan bridging and clinical development strategy.
Regulators
- Technical review: Pharmaceuticals and Medical Devices Agency (PMDA)
- Authority: Ministry of Health, Labour and Welfare (MHLW)
- Official portal: https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html
Registration Pathway
During the limited-time free period, sign in or register to view the complete pharmaceutical country report.